Tham khảo Liệu_pháp_hormone_thay_thế

  1. 1 2
  2. 1 2
  3. 1 2 3
  4. ↑ Shuster, Lynne T.; Rhodes, Deborah J.; Gostout, Bobbie S.; Grossardt, Brandon R.; Rocca, Walter A. (2010). “Premature menopause or early menopause: Long-term health consequences”. Maturitas 65 (2): 161–166. ISSN 0378-5122. PMC 2815011. PMID 19733988. doi:10.1016/j.maturitas.2009.08.003. 
  5. ↑ Eden, K.J., & Wylie, K.R. (2009). Quality of sexual life and menopause. Women’s Health, 5 (4), 385-396. doi:10.2217/whe.09.24
  6. ↑ Ziaei, S., Moghasemi, M., & Faghihzadeh, S. (2010). Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climateric, 13, 147-156. doi:10.1016/j.maturitas.2006.04.014
  7. ↑ Writing Group for the Women's Health Initiative Investigators (2002). “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial”. JAMA 288 (3): 321–333. PMID 12117397. doi:10.1001/jama.288.3.321. 
  8. ↑ Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M và đồng nghiệp (tháng 2 năm 2009). “Breast cancer after use of estrogen plus progestin in postmenopausal women”. The New England Journal of Medicine 360 (6): 573–87. PMC 3963492. PMID 19196674. doi:10.1056/NEJMoa0807684. 
  9. ↑ “USPTF Consensus Statement”. 2012. 
  10. ↑ Kreatsoulas, C.; Anand, S. S. (2013). “Menopausal hormone therapy for the primary prevention of chronic conditions. U.S. Preventive Services Task Force Recommendation Statement” (pdf). Polskie Archiwum Medycyny Wewnetrznej 123 (3): 112–117. PMID 23396275. 
  11. ↑ Nelson, H. D.; Walker, M.; Zakher, B.; Mitchell, J. (2012). “Menopausal hormone therapy for the primary prevention of chronic conditions: A systematic review to update the U.S. Preventive Services Task Force recommendations”. Annals of Internal Medicine 157 (2): 104–113. PMID 22786830. doi:10.7326/0003-4819-157-2-201207170-00466. 
  12. ↑ Grossman, David C.; Curry, Susan J.; Owens, Douglas K.; Barry, Michael J.; Davidson, Karina W.; Doubeni, Chyke A.; Epling, John W.; Kemper, Alex R.; Krist, Alex H.; Kurth, Ann E.; Landefeld, C. Seth; Mangione, Carol M.; Phipps, Maureen G.; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien-Wen (ngày 12 tháng 12 năm 2017). “Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women”. JAMA 318 (22): 2224. PMID 29234814. doi:10.1001/jama.2017.18261. 
  13. ↑ Santen, RJ; Utian, WH (2010). “Executive Summary: Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement”. J Clin Endocrinol Metab. 95 S1–S66 (Supplement 1): s1–s66. doi:10.1210/jc.2009-2509. Truy cập ngày 16 tháng 1 năm 2015.